Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.

Authors:
J Gotlib J Cools

Leukemia 2008 Nov 9;22(11):1999-2010. Epub 2008 Oct 9.

Department of Medicine, Division of Hematology, Stanford Cancer Center, Stanford, CA 94305-5821, USA.

The year 2008 marks the fifth anniversary since the publication which identified the FIP1L1-PDGFRA fusion gene in patients with idiopathic hypereosinophilia. With the benefit of time, a more comprehensive picture has emerged regarding several characteristics of the fusion, including its incidence, biological features and the clinical profile of patients who carry the molecular rearrangement. A few prospective trials have now better defined the natural history of imatinib-treated FIP1L1-PDGFRA-positive patients, from which some basic conclusions can be drawn: the prognosis is outstanding, acquired resistance is exceedingly rare, but ongoing imatinib treatment is likely required to prevent relapse. The emergence of genetically assigned eosinophilias has led the World Health Organization in 2008 to adopt a semi-molecular classification scheme, with one subcategory named 'myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.' Molecular rearrangements involving other partner genes, such as ETV6 and JAK2, have also been associated with eosinophilic disorders, and will likely be assimilated into such classifications over time. Despite the molecularly defined eosinophilias comprising a small proportion of cases compared to the aggregate of other subtypes of hypereosinophilia, their recognition is critical because of the availability of highly effective molecularly targeted therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1038/leu.2008.287DOI Listing
November 2008
2 Reads

Publication Analysis

Top Keywords

defined eosinophilias
8
molecularly defined
8
led health
4
health organization
4
eosinophilias led
4
assigned eosinophilias
4
relapse emergence
4
emergence genetically
4
genetically assigned
4
organization 2008
4
2008 adopt
4
named 'myeloid
4
'myeloid lymphoid
4
lymphoid neoplasms
4
subcategory named
4
scheme subcategory
4
adopt semi-molecular
4
semi-molecular classification
4
classification scheme
4
prevent relapse
4

References

(Supplied by CrossRef)

B Bain et al.
2001

AD Klion et al.
Blood 2003

HU Simon et al.
N Eng J Med 1999

F Roufosse et al.
Allergy 2004

MJ Chusid et al.
Medicine 1975

BJ Bain et al.
2008

BJ Bain et al.
2008

J Cools et al.
N Engl J Med 2003

M Baccarani et al.
Haematologica 2007

JV Jovanovic et al.
Blood 2007

A Pardanani et al.
Blood 2004

Similar Publications